SCHEMBL7147738

SCHEMBL7147738

O=Cc1cc(OCCCc2ccccc2)ccc1OCc1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.49
HTR1A P08908 2/20 0.49
DRD2 P14416 2/20 0.49
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TUBB1 Q9H4B7 1/20 0.44
PTGES O14684 1/20 0.43
ALOX5 P09917 1/20 0.43
PPARG P37231 1/20 0.43
ADRB2 P07550 1/20 0.43
RAF1 P04049 3/20 0.42
MAP2K1 Q02750 3/20 0.42
SYK P43405 1/20 0.42
MET P08581 1/20 0.42
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
S1PR1 P21453 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7143453 0.87 PTGES (0.49) HTR1ATUBB1PTGESALOX5PPARG
SCHEMBL7148350 0.87 PTGES (0.53) DRD2PTGESALOX5PPARGADRB2
SCHEMBL15474708 0.81 SYK (0.63) ABCB1HTR1ADRD2KDM4EALDH1A1
SCHEMBL7143354 0.81 BCHE (0.47) KDM4EALDH1A1SMN1; SMN2PTGESALOX5
SCHEMBL15475096 0.80 TUBB1 (0.61) KDM4EALDH1A1SMN1; SMN2TUBB1SYK
SCHEMBL7146459 0.80 PTGES (0.57) ALDH1A1SMN1; SMN2PTGESALOX5PPARG
SCHEMBL7149340 0.79 MAOB (0.43) PTGESALOX5PPARGADRB2MAOA
SCHEMBL5215714 0.77 ALDH1A1 (0.53) ABCB1HTR1ADRD2KDM4EALDH1A1
SCHEMBL3615463 0.76 MAOB (0.58) SMN1; SMN2TUBB1ALOX5MAOAMAOB
SCHEMBL4937535 0.75 PTGDR2 (0.52) ABCB1HTR1ADRD2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US disclosed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US disclosed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP disclosed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037901-A1 Thiazolidinecarboxyl acids TPMT, NAT1, THRA ABCB1 111/4885HTR1A 1181/4885DRD2 3278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.